Navigation Links
NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
Date:7/31/2009

SAN MATEO, Calif., July 31 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Friday, August 7, 2009 at 9:00 a.m. ET (6:00 a.m. PT) to report results for its second quarter 2009.

The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.

To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

A replay of the conference call will be available beginning August 7, 2009 at 12:00 p.m. ET (9:00 a.m. PT) and ending on August 17, 2009 by dialing 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 329620. A replay of the webcast will also be available on the corporate website for one month, through September 7, 2009.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza((TM)), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe Ltd., a subsidiary of Astellas Pharma Inc. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and was given a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to the timing and outcome of regulatory decisions and label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA, including the PDUFA date for the NDA; the timing and size of potential product launch of Qutenza; the tolerability profile and/or benefits of NeurogesX' product candidates and potential development partners for NeurogesX' early-stage products. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the FDA may request additional clinical trials or other information prior to granting approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.                     The Ruth Group
    Stephen Ghiglieri                   Sara Pellegrino (investors)
    Chief Financial Officer             (646) 536-7002
    (650) 358-3310                      spellegrino@theruthgroup.com

                                        Jason Rando (media)
                                        (646) 536-7025
                                        jrando@theruthgroup.com

'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX Added to Russell 3000 Index
2. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
3. NeurogesX to Present at Needham Life Sciences Conference
4. NeurogesX Receives European Commission Approval for Qutenza(TM)
5. NeurogesX Reports First Quarter 2009 Results
6. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
7. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
8. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
9. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
10. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
11. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 25, 2017 , ... ... will garner a better understanding of the considerations needed for designing ideal guide ... The use of CRISPR-Cas9 to create targeted double-strand breaks in genomic DNA has ...
(Date:7/26/2017)... ... 2017 , ... NLP Logix today announced a collaboration to ... Mayo Clinic and the experience in developing and deploying artificial intelligence solutions by ... Azure platform and will focus on assisting physicians to more accurately and efficiently ...
(Date:7/26/2017)... N.J. , July 26, 2017  Nurse practitioners play ... to the findings of a Merck Manuals survey ... recent medical conference, revealed that most (88 percent) believe they ... diagnoses, treatments and prescriptions. ... Merck Manuals survey of 210 ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... microbiome and improve efficiency of livestock farming while reducing the use of antibiotics ... additional intellectual property from Cornell University. , These new proprietary technologies expand ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
Breaking Biology News(10 mins):